Condition: Advanced Solid Tumors Harboring RAS Mutations or Amplifications · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.
This description comes directly from the study's public registry record.
Rongfu Mao · +86 021-61053363 · rongfu.mao@hengrui.com
Jizhao Li · +86-021-61053363 · jizhao.li.jl565@hengrui.com
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07189949